AG
TTPH

Aperio Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Aperio Group’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,074
Closed -$10K – 2968
2019
Q2 		$10K Buy
1,074
+494
+85% +$9.09K ﹤0.01% 2790
2019
Q1 		$16K Buy
+580
New +$14.8K ﹤0.01% 2281

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aperio Group's TTPH Position: Q3 2019 in Review

Aperio Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 1,074 shares — an estimated $10K sold.

Aperio Group first reported a position in TTPH in Q1 2019 and held it in 2 quarters. The position peaked at $16K in Q1 2019. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Aperio Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 1,074 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $10K.
  • Aperio Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Aperio Group's Tetraphase Pharmaceuticals, Inc. position peaked at $16K in Q1 2019.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.